论文部分内容阅读
目的观察康莱特注射液治疗晚期非小细胞肺癌的临床疗效。方法将60例原发性肺癌随机分为两组:观察组和对照组均为30例。观察组采用康莱特注射液静脉点滴治疗;对照组采用一线化疗方案静脉点滴全身化疗。观察临床近期疗效(包括有效率及稳定率)、Karnofsky评分、体重变化、不良反应。结果上述观察的各项指标,除近期疗效有效率相近,两组比较差异无统计学意义(χ2=0.325,P>0.05),观察组的karnofsky评分、体重变化、不良反应等情况均明显优于对照组,两组比较差异有统计学意义(χ2=6.550,P<0.01)。结论康莱特注射液治疗晚期非小细胞肺癌较应用一线化疗方案化疗能明显改善症状,提高生存质量,使患者体重明显增加,而且没有明显毒副反应。
Objective To observe the clinical effect of Kanglaite Injection in the treatment of advanced non-small cell lung cancer. Methods Sixty patients with primary lung cancer were randomly divided into two groups: the observation group and the control group were 30 cases. The observation group was treated with intravenous infusion of Kanglaite injection; the control group received intravenous systemic chemotherapy with first-line chemotherapy. Short-term clinical efficacy (including efficiency and stability), Karnofsky score, weight changes, and adverse reactions were observed. Results The above indicators observed, in addition to the effectiveness of the short-term efficacy similar to the two groups was no significant difference (χ2 = 0.325, P> 0.05), the observation group karnofsky score, weight changes, adverse reactions were significantly better than The difference between the two groups was statistically significant (χ2 = 6.550, P <0.01). Conclusion Kanglaite injection of chemotherapy for advanced non-small cell lung cancer compared with first-line chemotherapy can significantly improve symptoms and improve quality of life, so that patients with significant weight gain, and no significant side effects.